



- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61P 37/08* (2006.01)
- (21) **International Application Number:**
PCT/EP2024/060094
- (22) **International Filing Date:**
12 April 2024 (12.04.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
23168134.7 14 April 2023 (14.04.2023) EP
23168136.2 14 April 2023 (14.04.2023) EP
- (71) **Applicant: KYMAB LIMITED** [GB/GB]; The Bennet Building (B930), Babraham Research Campus, Cambridge CB22 3AT (GB).
- (72) **Inventors: ZHU, Chen;** Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **GUP-TA, Ashi;** Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **GOODING, Tam-**

era; Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **BADIALI, Luca;** Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **JÖRG, Susanne;** Lonza Ltd, Münchensteinerstrasse 38, CH-4002 Basel (CH). **ENGELKE, Laura;** Lonza Ltd, Münchensteinerstrasse 38, CH-4002 Basel (CH). **JERE, Dhananjay;** Lonza Ltd, Münchensteinerstrasse 38, CH-4002 Basel (CH). **PATKE, Sanket;** Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US).

(74) **Agent: PEARS, Michael;** Potter Clarkson, Chapel Quarter, Mount Street, Nottingham NG1 6HQ (GB).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) **Title:** PHARMACEUTICAL FORMULATIONS CONTAINING ANTI-OX40L ANTIBODIES




FIG. 1A

(57) **Abstract:** The present disclosure provides aqueous pharmaceutical formulations comprising anti-OX40L antibodies or antigen binding fragment thereof for treating or preventing OX40L-mediated diseases or conditions in humans. The present disclosure also provides containers and kits comprising the aqueous pharmaceutical formulations and the use of these aqueous pharmaceutical formulations in treating or preventing OX40L-mediated diseases or conditions in humans.

[Continued on next page]

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*